The estimated Net Worth of Francis A De Souza is at least $40.4 Million dollars as of 21 February 2023. Mr. Souza owns over 23,473 units of Illumina Inc stock worth over $12,535,304 and over the last 13 years he sold ILMN stock worth over $26,334,231. In addition, he makes $1,521,950 as President, Chief Executive Officer, and Director at Illumina Inc.
Francis has made over 39 trades of the Illumina Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 23,473 units of ILMN stock worth $2,930,135 on 21 February 2023.
The largest trade he's ever made was exercising 49,219 units of Illumina Inc stock on 3 March 2016 worth over $6,144,008. On average, Francis trades about 2,975 units every 34 days since 2011. As of 21 February 2023 he still owns at least 100,419 units of Illumina Inc stock.
You can see the complete history of Mr. Souza stock trades at the bottom of the page.
Francis A. deSouza is the President, Chief Executive Officer, Director of Illumina Inc. Mr. deSouza has served as President since December 2013 and as a Director since January 2014. Prior to joining Illumina, Mr. deSouza was President, Products and Services, of Symantec Corporation, a NASDAQ-listed software technology company, from 2011 to 2013, and Mr. deSouza served as Symantec’s Senior Vice President, Enterprise Security Group, from 2009 to 2011. Prior to joining Symantec, from 2001 to 2006, he was Founder and Chief Executive Officer of IMlogic, Inc. an enterprise instant messaging software company that was acquired by Symantec in 2006, and Mr. deSouza served as a Product Unit Manager, Real-time Collaboration Group, at Microsoft Corporation from 1998 to 2001. Prior to joining Microsoft, from 1997 to 1998, Mr. deSouza was co-founder and Chief Executive Officer of Flash Communications, an enterprise instant messaging company that was acquired by Microsoft in 1998. Mr. deSouza is Chairman of the board of directors of MedHelp International, a privately-held online health community. Mr. deSouza received a bachelor’s degree in electrical engineering and computer science with a minor in economics and a master’s degree from Massachusetts Institute of Technology.
As the President, Chief Executive Officer, and Director of Illumina Inc, the total compensation of Francis deSouza at Illumina Inc is $1,521,950. There are 5 executives at Illumina Inc getting paid more, with Mostafa Ronaghi having the highest compensation of $3,541,310.
Francis deSouza is 49, he's been the President, Chief Executive Officer, and Director of Illumina Inc since 2016. There are 17 older and 4 younger executives at Illumina Inc. The oldest executive at Illumina Inc is John Thompson, 71, who is the Lead Independent Director.
Francis's mailing address filed with the SEC is 500 SOUTH BUENA VISTA STREET, , BURBANK, CA, 91521.
Over the last 21 years, insiders at Illumina Inc have traded over $412,190,379 worth of Illumina Inc stock and bought 13,386 units worth $1,243,499 . The most active insiders traders include John Wendell Thompson, Jay T Flatley, and Robert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of $954,700. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth $991,676.
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Illumina Inc executives and other stock owners filed with the SEC include: